FDA OKs Neuralstem Trial Treating Spinal Cord Injuries With Stem Cells (CUR)

FDA OKs Neuralstem Trial Treating Spinal Cord Injuries With Stem Cells

The FDA has given Neuralstem (NYSEMKT: CUR ) clearance to test its human spinal stem cell transplantation therapy, NSI-566, in patients with spinal cord injuries. The phase 1 trial will test the cell therapy on up to eight patients between one and two years after an injury that caused complete paralysis below their spinal cord damage. The first four patients will receive a lower dose, and the next four will receive a larger dose.

The primary purpose of the trial is to evaluate the safety of NSI-566, but Neuralstem will also evaluate how well the graft survives and whether it's able to increase functions, including motor and sensory function and bowel and bladder function.

Studies in paralyzed rats demonstrated that NSI-566 turned into neurons that extended across the break in the spinal cord, resulting in recovery of significant locomotor function.

NSI-566 has already been tested in a phase 1 trial in patients with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease. Another clinical trial in ALS is expected to start this quarter.

link

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.